Agonist-antagonist

Synaptic receptors

For synaptic receptors, an agonist is a compound that increases the activation of the receptor by binding directly to it or by increasing the amount of time neurotransmitters are in the synaptic cleft. An antagonist is a compound that has the opposite effect of an agonist. It decreases the activation of a synaptic receptor by binding and blocking neurotransmitters from binding or by decreasing the amount of time neurotransmitters are in the synaptic cleft. These actions can be achieved via multiple mechanisms. A common mechanism for agonists is reuptake inhibition, where the agonist blocks neurotransmitters from reentering the pre-synaptic axon terminal. This gives the neurotransmitter more time in the synaptic cleft to act on the synaptic receptors. Conversely, antagonists often bind directly to receptors in the synaptic cleft, effectively blocking neurotransmitters from binding.

At the alpha adrenoceptors, (R)-3-nitrobiphenyline is an α2C selective agonist as well as being a weak antagonist at the α and α subtypes.

Agonist-antagonist opioids

The best known agonist-antagonists are opioids. Examples of such opioids are:

• pentazocine, agonist at the kappa (κ) and sigma (σ) with weak antagonist action at the mu opioid receptor (μ)
• butorphanol, pure agonist at κ-opioid receptor, partial agonist at μ-opioid receptor, and antagonist activity at the delta opioid receptor (δ)
• nalbuphine, κ-agonist/μ-antagonist analgesic

Agonist–antagonist opioids usually have a ceiling effect – over particular dose they don't increase their potency. Hence agonist–antagonist opioids have a lower addiction potential but also lower analgesic efficacy and are more likely to produce psychotomimetic effects.

Agonist–antagonist opioids that activate mu opioid receptors while blocking delta produce analgesia without the development of tolerance.

References

References

1. (March 1991). "Opioid agonist-antagonist drugs in acute and chronic pain states". Drugs.
2. (August 2007). "Alpha2-adrenoreceptors profile modulation. 3.1 (R)-(+)-m-nitrobiphenyline, a new efficient and alpha2C-subtype selective agonist". Journal of Medicinal Chemistry.
3. (November 2010). "Fruitful adrenergic α(2C)-agonism/α(2A)-antagonism combination to prevent and contrast morphine tolerance and dependence". Journal of Medicinal Chemistry.
4. (17 July 1991). "AMA Drug Evaluations Annual 1991". JAMA: The Journal of the American Medical Association.
5. (June 2005). "Butorphanol: effects of a prototypical agonist-antagonist analgesic on kappa-opioid receptors". Journal of Pharmacological Sciences.
6. (February 1985). "Nalbuphine". Drug and Alcohol Dependence.
7. (March 1992). "Advantages and guidelines for using opioid agonist-antagonist analgesics". The Veterinary Clinics of North America. Small Animal Practice.
8. (December 1987). "Benefit-risk ratio of agonist-antagonist analgesics". Drug and Alcohol Dependence.
9. (July 2009). "Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profile". British Journal of Anaesthesia.